Here, we characterize a novel mechanism, in which a PIK3R1 fusion paradoxically activates the ERK1/2 pathway, increases ovarian cancer cell migration and chemoresistance, and thereby potentially facilitates metastatic dissemination. Here, MAPK3 is linked to ovarian carcinoma.